New PET-MRI tracer could sharpen view of Kids' brain tumors
NCT ID NCT05555550
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 32 times
Summary
This early-phase trial at Children's Hospital of Philadelphia is testing whether a radioactive tracer called 18F-Fluciclovine (Axumin) can improve PET-MRI scans for children and young adults with low-grade glioma. About 30 participants will receive the tracer before starting treatment, then again at 3 months and 1 year. The goal is to see if changes in tracer uptake better reflect tumor response than standard MRI alone, while also checking safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
The Children s Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-Fluciclovine (Axumin), a radioactive tracer injected before PET-MRI imaging
What this could lead to
If successful, this imaging method could help doctors see sooner whether a child's brain tumor is responding to treatment, potentially guiding therapy adjustments.
What could go wrong
This is a very early, small study (30 participants) focused on imaging accuracy, not treatment. The tracer may not prove more useful than standard MRI, and safety in children is still being checked.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.